Company / Shareholders' Equity
Cytokinetics Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$659.6M
FY2025
5-year range
-$659.6M / $243.9M
FY2021-FY2025
Trend
-387.3%
vs FY2024
Sector context
#210 of 213
Health Care
What the data says
Cytokinetics reports negative total equity of -$660M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$660M in FY2025.
Declined from -$386M to -$660M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 213This company -$659.6M Sector average $2.5B
▼
-125.9% below sector average
Key checks
Key Insights
- In FY2025, shareholders' equity decreased 387.3% year-over-year.
- Ranks #210 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.12 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$659.6M | -387.3% |
| FY2024 | -$135.4M | +65.0% |
| FY2023 | -$386.3M | -258.0% |
| FY2022 | -$107.9M | -144.2% |
| FY2021 | $243.9M | +115.1% |
| FY2020 | $113.4M | +1136.7% |
| FY2019 | -$10.9M | -142.2% |
| FY2018 | $25.9M | -76.4% |
| FY2017 | $109.8M | +16.4% |
| FY2016 | $94.4M | +37.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026